Market Insight - Obesity: what next after the CB1 antagonists' failure?
04 November 2008
Jacob Plieth
Please Login to read the full article.
04 November 2008
Jacob Plieth
The European regulator's recent decision to suspend sales of
Sanofi-Aventis's Acomplia (rimonabant) came hot on the heels of setbacks with two other late-stage CB1 antagonist agents, and the developments have put the spotlight on obesity as a therapy area and made some observers question whether...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vivus narrows indication for Qnexa obesity drug to FDA to enable Q2 2012 approval
- EMA to rethink orlistat in light of rare liver injuries
- FDA 'feasible' CV design spurs Orexigen to resurrect Contrave
- Researchers knock EMA over trial reporting and access to 'commercial' raw data
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
